

WO9947140

Title:

TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS

Abstract:

In a preferred embodiment, a method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to the surface or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/445		A1	(11) International Publication Number: WO 99/47140 (43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: PCT/US99/04412 (22) International Filing Date: 1 March 1999 (01.03.99) (30) Priority Data: 60/078,307 17 March 1998 (17.03.98) US (71)(72) Applicant and Inventor: MARGOLIN, Solomon, B. [US/US]; 6723 Desco Drive, Dallas, TX 75225 (US). (74) Agent: CROZIER, John, H.; 1934 Huntington Turnpike, Trumbull, CT 06611-5116 (US).		(81) Designated States: AU, CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: TOPICAL ANTISEPTIC COMPOSITIONS AND METHODS (57) Abstract In a preferred embodiment, a method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to the surface or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DescriptionTopical Antiseptic Compositions and Methods5 Technical Field

The present invention relates to antiseptic compositions and, more particularly, to an ointment, cream, or foam containing pirfenidone and/or related compounds, for disinfecting the skin.

10

Background Art

A large number of various disinfecting preparations are known. When hygienic purposes are concerned, disinfection becomes rather difficult,
15 because it is necessary to reconcile an efficient antiseptic effect with demonstrable harmlessness with respect to the skin. Many such known disinfecting preparations cause adverse reactions when applied to the skin, such as skin irritation, even though the
20 preparations may have satisfactory antiseptic properties.

Accordingly, it is a principal object of the present invention to provide new disinfectant compositions and methods of application which are
25 harmless to the skin, while exerting a marked killing action on microorganisms which develop on or in the outer layers of the dermis.

It is a further object of the invention to provide such a disinfectant composition as an ointment, cream,
30 or foam formed in an aqueous dispersion of one or more substances, the water of the dispersion being dissolved or emulsified therein and carrying suitable fatty solvents and an active ingredient.

35

-2-

It is an additional object of the invention to provide such a disinfectant composition that is self-sanitizing, that is, the composition causes the complete destruction of bacteria and fungi after the composition
5 has been deliberately inoculated with contaminating infectious microbes.

It is another object of the invention to provide such a disinfectant composition that can be utilized as an antimicrobial disinfectant for various inanimate
10 objects.

It is yet a further object of the invention to provide such a disinfectant that is long lasting because of the persistence of the active agent on the surface of the skin.

15 It is yet a an additional object of the invention to provide such a disinfectant that penetrates into the several outer layer of the dermis.

It is yet another object of the invention to provide such a disinfectant that is harmless with
20 respect to the skin.

Other objects of the present invention, as well as particular features, elements, and advantages thereof, will be elucidated in, or be apparent from, the following description and the accompanying drawing
25 figures.

Disclosure of Invention

The present invention achieves the above objects, among others, by providing, in a preferred embodiment, a
30 method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to said surface or layers a pharmaceutical substance including an effective amount
35 of one or more 2-(1H) pyridone compound(s).

-3-

Best Mode for Carrying Out the Invention

The present invention relates to medical compositions and methods for the novel antiseptic topical treatment of microbial (bacteria, fungi, viruses) on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, which composition comprises pirfenidone (5-methyl-1-phenyl-2-(1H) pyridone) and/or related compounds in an appropriate formulation of a pharmaceutical topical ointment, cream, lotion, or solution.

Furthermore, the present invention is directed to a non-irritating, emollient, germicidal pharmaceutical composition. This composition affords a method of using the formulations as antiseptics for untoward skin conditions such as a dermal wound, bruise, or microbial infections, as well as for other damaged external body surface tissues, by safely penetrating outer layers of skin and related tissues or structures. In addition, the antimicrobial data indicate the compositions to be self-sanitizing, since the composition can cause marked elimination or complete destruction of bacteria and fungi after the composition has been deliberately inoculated with infectious microbes. The composition also can be utilized as an antimicrobial disinfectant for various inanimate objects. As formulated, the composition is stable for many months at temperatures of 25 degrees Centigrade or less.

The invention provides an ointment, cream, or foam formed in an aqueous dispersion of one or more active substances, the water of the dispersion being dissolved or emulsified therein and carrying suitable fatty solvents and the active ingredient(s), pirfenidone and/or related compounds. The preferred concentration of the active ingredient(s) is from about 5 to about 10 weight percent.

-4-

The composition of the present invention provides an effective microbial sanitizer, disinfectant, and barrier in one composition. The antimicrobial effects are very marked as evidenced by the several tests set forth below.

By adding suitable ingredients to the active compound(s), such as glycerine, natural colorants, surfactants, emulsifiers, and oils, it is possible to produce antiseptic products which are presented as antiseptic lotions, antiseptic solutions, lotions, antiseptic ointments, and antiseptic foams. In the case of antiseptic ointments, creams, lotions, and solutions, the cited bactericidal, fungicidal, and virucidal effects are recognizable within minutes. The antiseptic products and their method of manufacture are illustrated below.

The ingredients of the compositions include USP products: white petrolatum, propylene glycol 400, and stearyl alcohol, for example, all appropriately dissolved and emulsified into purified distilled water. In order to illustrate the general dermatological composition of the present invention, a base composition of the following can be prepared:

MODIFIED USP HYDROPHILIC OINTMENT (5.0% PIRFENIDONE)

<u>Ingredient</u>	<u>Percent by Weight</u>
Pirfenidone (USAN) Powder	5.0
Propylene Glycol 400 USP	23.5
Sterile Distilled Water	30.5
Stearyl Alcohol USP	20.5
White Petrolatum USP	<u>20.5</u>
TOTAL: 100.0	

MODIFIED USP HYDROPHILIC OINTMENT (10.0% PIRFENIDONE)

<u>Ingredient</u>	<u>Percent by Weight</u>
Pirfenidone (USAN) Powder	10.0
Propylene Glycol 400 USP	14.3
Sterile Distilled Water	41.7

-5-

Stearyl Alcohol USP	17.0
White Petrolatum USP	<u>17.0</u>
TOTAL:	100.0

5 It is important to mix and melt the aqueous
components (pirfenidone, propylene glycol 400, and
water), heating to about 70 degrees Centigrade
independently from the lipophilic phases (stearyl
alcohol and white petrolatum) which also must be heated
10 to about 70 degrees Centigrade to facilitate mixing and
melting. When each phase has been adequately mixed and
melted, they are combined and cooled with rapid
stirring, until the mixture congeals into a fluffy,
white ointment. The temperature of the ointment when it
15 congeals will be about 40-45 degrees Centigrade.
(Failure to adequately mix by vigorous stirring during
the chilling step will result in the separation of the
two solvent phases, and the emulsifying properties of
the formulation will have been lost.)

20 A critical feature of the compositions of this
invention is the chemical stability of the active
ingredient(s), pirfenidone and/or related compounds.
Crystalline pirfenidone is stable at room temperature
(i.e., 25 degrees Centigrade) for more than five years.
25 The formulations described above are stable for two
years or longer at 25 degrees Centigrade (room
temperature), based upon chemical assays and upon
physical characteristics (color, plasticity, active
ingredient dispersion and suspension).

30 The formulations described above have demonstrated
their efficacy against the following microorganisms:

Escherichia coli
Staphylococcus aureus
Bacillus subtilis
35 Pseudomonas aeruginosa
Proteus vulgaris
Trichophyton mentagorphytes

-6-

Candida albicans
Aspergillus niger
Influenza virus
Coxsackie virus
Herpes virus
Papilloma virus

5

10

15

20

25

30

35

-7-

TABLE IPRELIMINARY ANTIMICROBIAL TEST OF PIRFENIDONE

		Pirfenidone Concentrations, wt. %					
		2.0	0.0*	5.0	0.0*	10.0	0.0*
5		GROWTH SCORES (0 TO 10)***					
	<u>BACTERIA:</u>						
	Proteus vulgaris	-**	-	0	10	0	10
	Escherichia coli	-	-	0	10	0	10
	Pseudomonas aeruginosa	1	10	0	10	0	10
10	Bacillus subtilis	-	-	0	10	0	10
	Staphylococcus aureus	-	-	0	10	0	10
	<u>FUNGI:</u>						
	Candida albicans	-	-	2	10	0	10
15	Aspergillus niger	-	-	0	10	0	10
	Trychophton						
	mentagrophytes	-	-	2	10	0	10
<hr/>							
	* Control.						
20	** Not tested.						
	*** 1=very slight						
	2=slight						
	3=slight to moderate						
	4=moderate						
25	<u>10=total plate growth (maximal growth)</u>						
	(End of Table I)						

30

35

METHODS FOR MEASURING ANTIMICROBIAL ACTIVITY
IN TOPICAL PREPARATIONS FOR TABLE I:

TESTING DISINFECTING ACTIVITY

5 A nutritive broth is prepared by dissolving a
commercial nutritive substance in 1000 ml. of sterile
distilled water. The solution is heated to 100 degrees
Centigrade and poured into sterile Petri dishes under
sterile conditions. After cooling and solidifying, the
10 gels are then kept at 37 degrees Centigrade for the
specified number of hours or days.

 Using the modified USP hydrophilic ointment with
and without pirfenidone, the procedure outlined below
was followed to determine bacterial and fungal counts.
15 This procedure is based on that described in the booklet
"microbiological Examination of Topical Drugs and
Cosmetics," published by the Division of Microbiology,
United States Food and Drug Administration, January 7,
1969.

20

Bacteria Plate Count:

 Ten (10) grams of sample is aseptically measured
into 90 ml. diluent (Butterfield's phosphate diluent
with azolectin and Tween 80) to make a 10 (1 pwr)
25 dilution. Decimal dilutions from 10 (1 pwr) to 10 (4
pwr) are made using 90 ml. dilution blanks of
Butterfield's phosphate diluent. Duplicate plates from
each of the above dilutions are made following
directions of AOAC, 11th ed., 1970, pp 842-843, 41.015,
30 except for the use of Trypticase Soy Agar (42-45 degrees
Centigrade) in place of plate count agar.

 One ml. of each dilution is placed into a Petri
dish and Trypticase Soy Agar is added within 15 minutes
from the time of original dilution. Plates were
35 incubated for 48 hours at 35 degrees Centigrade, and
duplicate plates for each dilution with colony counts in
the range of 30 to 300 per plate are counted and

-9-

averaged. Counts are reported as aerobic plate count per gram of sample.

Fungi Plate Count:

5 Decimal dilutions as described above for the
aerobic bacteria plate count are prepared. Aliquots of
1.0 ml. of each dilution are delivered to each of
quadruplicate (4) plates. Plates are poured with 20-25
ml. of "Sabouraud's Dextrose Agar. Two plates are
10 incubated at 37 degrees Centigrade, and other two plates
are incubated at room temperature (26 degrees
Centigrade) for seven days. Counts of duplicate plates
are averaged and reported, in each case, as counts per
gram of sample.

15

20

25

30

35

-10-

TABLE IIADDITIONAL PIRFENIDONE ANTI-MICROBIAL PILOT TESTSTest # 1:.

5 A 2.0% solution of pirfenidone was prepared in
nutrient broth, and then was inoculated with *Pseudomonas*
aeruginosa. After 48 hours of incubation at 37 degrees
Centigrade, the nutrient broth failed to evidence any
growth. Then a standard loopful from this pirfenidone
10 treated broth was streaked on Tryptic Soy Agar (Difco)
and incubated for 5 days at 37 degrees Centigrade; no
growth of *Pseudomonas aeruginosa* was seen.

Test # 2:

15 A 5.0% solution of pirfenidone in Tryptic Soy Agar
(Difco) was formulated. Pirfenidone was dissolved in
hot agar. When permitted to cool to room temperature
(26 degrees Centigrade), pirfenidone became a suspension
in a uniform slightly opaque manner throughout the
20 agar. At 10.0% of pirfenidone in Tryptic Soy Agar, the
drug formed a uniformly opaque suspension in the agar.
Growth was completely inhibited at both concentrations
of the following organisms:

25

30

35

-11-

Antiseptic Effect Against Bacteria:

Agar inoculated with the following bacteria, and
incubated at 37 degrees Centigrade:

	Escherichia coli	ATCC	#11229
5	Proteus vulgaris	ATCC	# 6538
	Bacillus subtilis	ATCC	#19659
	Staphylococcus aureus	ATCC	#13315
	Pseudomonas aeruginosa	ATCC	#15442

10 Antiseptic Effect Against Fungi:

Agar inoculated with the following fungi and
incubated at 26 degrees Centigrade:

	Trichophyton mentagrophytes	ATCC	# 9129
	Candida albicans	ATCC	#10259
15	Aspergillus niger	ATCC	# 9642

(End of Table II)

20

25

30

35

-12-

TABLE III
CHALLENGE TESTS

Challenge tests were conducted of pirfenidone
5 against microbial inoculations into: (a) nutrient broth,
and (b) 5.0% or 10.0% pirfenidone ointments (modified
USP hydrophilic ointment). A *Pseudomonas aeruginosa*
inoculation into broth served as a positive control.

The bacterial mixture for inoculation consisted
10 of:

Escherichia coli
Proteus vulgaris
Bacillus subtilis
Staphylococcus aureus
15 *Pseudomonas aeruginosa*

The fungal mixture for inoculating consisted of:
Trichophyton mentagrophytes
Candida albicans
Aspergillus niger

20 After seven days, the respective cultures were
plated out to determine the number of microbes present.
The results as compared with the baseline number of
microbes present when the cultures were inoculated
follows:

25

30

35

-13-

	<u>Pseudomonas</u>	<u>Mixed</u>	<u>Mixed</u>
	<u>(Positive Control)</u>	<u>Bacteria</u>	<u>Fungi</u>
	<u>Microbes per gm. of Sample (After 7 days)</u>		
	Baseline (day 1)		
5	(No Pirfenidone)	52 million	23 million
		(100.0%)	(100.0%)
	2.0% Broth Solution	<100	530,000
	(Pirfenidone)	(0.0%)	(2.3%)
10			2,000
			(0.08%)
	5.0% Ointment	510,000	57,000
	(Pirfenidone)	0.01%	(0.02%)
			350
			(0.002%)
	10.0% Ointment	2,600	70,000
15	(Pirfenidone)	(0.0001%)	(0.03%)
			<10
			(0.0%)
	(End of Table III)		

20

25

30

35

-14-

TABLE IV
CHALLENGE EXPERIMENTS

Challenge experiments were conducted over four weeks for pirfenidone ointment against mixed microbial inoculations into: (a) nutrient broth, and (b) 5.0% or 10.0% pirfenidone ointments. A *Pseudomonas aeruginosa* inoculation into broth served as a positive control.

The bacterial mixture for inoculation consisted of:

	<i>Escherichia coli</i>	ATCC	#11229
	<i>Proteus vulgaris</i>	ATCC	# 6538
	<i>Bacillus subtilis</i>	ATCC	#19659
	<i>Staphylococcus aureus</i>	ATCC	#13315
15	<i>Pseudomonas aeruginosa</i>	ATCC	#15442

The fungal mixture for inoculation consisted of:

	<i>Trichophyton mentagrophytes</i>	ATCC	# 9129
	<i>Candida albicans</i>	ATCC	#10259
	<i>Aspergillus niger</i>	ATCC	# 9642

At weekly intervals for four weeks, the respective cultures were plated out into Petri dishes to determine the number of microbes present. The results as compared with the baseline number of microbes present when the cultures were first inoculated follow:

25

30

35

-15-

		<u>Pseudomonas</u>	<u>Mixed</u>	<u>Mixed</u>
		<u>(Positive Control)</u>	<u>Bacteria</u>	<u>Fungi</u>
	Baseline (day 1)			
	(No Pirfenidone)	52 million	23 million	240,000
5		(100.0%)	(100.0%)	(100.0%)
	2.0% Broth Solution (Control)			
	(With Pirfenidone)			
	After 1 week:	<100	590,000	<100
10		(0.0%)	(2.3%)	(0.0%)
	After 2 weeks:	<10	690,000	<10
		(0.0%)	(3.0%)	(0.0%)
	After 3 weeks:	<10	1,100,000	<10
		(0.0%)	(4.4%)	(0.0%)
15	After 4 weeks:	<10	510,000	<10
		(0.0%)	(2.2%)	(0.0%)
	5.0% Ointment			
	(Pirfenidone)			
20	After 1 week:	510,000	57,000	<100
		(0.98%)	(0.25%)	(0.0%)
	After 2 weeks:	1,480,000	68,000	<10
		(2.8%)	(0.30%)	(0.0%)
	After 3 weeks:	790,000	65,000	<100
25		(1.5%)	(0.28%)	(0.0%)
	After 4 weeks:	180,000	44,000	<10
		(0.34%)	(0.19%)	(0.0%)
	10.0% Ointment			
30	(Pirfenidone)			
	After 1 week:	260,000	70,000	<10
		(0.50%)	(0.30%)	(0.0%)
	After 2 weeks:	2,060,000	166,000	<10
		(3.9%)	(0.71%)	(0.0%)
35	After 3 weeks:	1,240,000	280,000	<10
		(2.2%)	(1.20%)	(0.0%)
	After 4 weeks:	1,020,000	131,000	<10

-16-

	(2.0%)	(0.57%)	(0.0%)
--	--------	---------	--------

(End of Table IV)

5

10

15

20

25

30

35

-17-

The data (Tables I, II, III, and IV) demonstrate that compositions (solutions or ointments) containing pirfenidone at concentrations of 2.0% to 10.0% are distinctly disinfective against aerobic pathogenic
5 bacteria and fungi in a manner typical of antiseptics, and their efficacy increases within a range of increasing concentrations. Disinfectant effects are greatly reduced at concentrations lower than 1.5%.

10 SAFETY

Primary Skin Irritation Tests:

According to several primary skin (abraded and non-abraded) irritant test in albino rabbits, the primary
15 irritation index is well below 0.5, and therefore the tests samples of the respective compositions cannot be classified as positive skin irritants.

Acute Topical Irritation/Local Toxicity Tests:

20 (1) Primary Rabbit Acute Eye Irritation Test
for 2.0% Pirfenidone Solution

Pirfenidone, as a 2.0% sterile aqueous solution was applied to the eye corneas of six albino rabbits, and failed to cause any irritation as evidenced by the
25 absence of hyperemia, edema, eye discomfort, or chemotaxis (Draize method). The eyes were carefully examined at 1.0 minutes, 30 minutes, and 3 hours after applying the solution, and then repeatedly examined for 10 days after the application of the pirfenidone
30 solution (0.1 ml. per eye).

(2) Primary Rabbit Acute Eye Irritation Test
for 10.0% Pirfenidone Modified USP Hydrophilic Ointment

Modified USP hydrophilic ointment containing 10.0% pirfenidone was applied to the right eye corneas of 6
35 albino rabbits and did not cause any irritation as evidenced by the absence of hyperemia, edema, eye discomfort, or chemotaxis (Draize method). The eyes were carefully examined at 1, 3, 8, 24, and 48 hours and

-18-

carefully re-examined daily for 10 days after the application of the ointment (100 milligrams per eye).

(3) Subacute (21 days) Dermal Local
and Systemic Toxicity in Albino Rabbits

5 Graded amounts of modified USP hydrophilic ointment containing 10.0% pirfenidone repeatedly was topically applied to the dorsal aspect of the clipped abraded or non-abraded skin of the back. The graded amounts of ointment were 200 mg/kg/day, 2000 mg/kg/day,
10 and 5000 mg/kg/day. The controls received 5000 mg/kg/day of the placebo vehicle ointment. The rabbits were observed carefully each day for signs of any irritation to the skin (erythema, edema, necrosis, etc.) and were scored according to the method of Draize. They
15 also were observed for any alterations in general appearance and behavior.

No evidence of irritation of the skin (abraded or non-abraded) was seen in any of the groups. No effect was seen at any dose level upon general appearance,
20 behavior, body weight gain, or upon any of the detailed hematological and blood chemistry values, or upon urinalyses. In addition, gross and histopathological examination of several vital organs and tissues failed to show any drug-related changes. In this subacute
25 rabbit experiment, the data indicates that 5000 mg/kg/day of a 10.0% pirfenidone ointment for 21 days is devoid of any demonstrable local or systemic toxicity.

ACUTE ORAL TOXICITY OF 10.0% PIRFENIDONE
HYDROPHILIC OINTMENT IN RODENTS

30 The acute toxicity of the composition cited, determined in female and male rats and/or mice, exceeds 5000 mg/kg/day when administered orally, or topically.

In fasted albino mice, the oral LD50 was
35 calculated to be 11,000 +/- 1,100 mg/kg of body weight. This was determined according to the mortality found over 14 days following administration of the six graded doses to groups of 7 mice per dose level. In fasted

-19-

albino rats, the oral LD50 was greater than 10,000 mg/kg body weight, since no deaths and no signs of toxicity occurred.

- 5 The following are illustrative examples of the various end use compositions of the invention.

EXAMPLE 1

A modified USP hydrophilic ointment composition
10 was prepared containing, however, 10.0% of pirfenidone. The composition was applied topically to patients who recently experienced lacerations which had become infected. No systemic antimicrobial agents were used. Remission of the infection occurred within 24 hours and
15 complete healing occurred within 5 to 10 days.

EXAMPLE 2

Modified USP hydrophilic ointment composition was
prepare containing 10.0% of pirfenidone. The
20 composition was applied topically daily to the toenails of patients with longstanding (several years) fungus infections of the toenails. These infections had been treated repeatedly with many types of antifungal agents without success. The pirfenidone ointment completely
25 cleared these fungus infections in 3 to 12 weeks, and the lesions did not recur on 2-year follow-ups. Pirfenidone is unusual in its ability to penetrate into the collagenous matrix of the toenail, and then into the dermal layers underneath the toenail.

30 The cited hydrophilic ointment also is very effective in successfully treating, as well as preventing, the fungus infections characteristic of "athlete's foot".

35

EXAMPLE 3

The composition was prepared and applied topically to patients having a bacterial infection and inflamed local rash at a rate of three times daily. Relief of

-20-

discomfort occurred within 1 to 3 hours, and complete healing along with clearing of the rash, was seen after 5 to 7 days.

5

EXAMPLE 4

The above cited hydrophilic composition was applied to patients having debraded skin due to a scalding burn. Improvement included reduced irritation within one hour and a marked remission was seen in 24
10 hours after commencement of treatment and subsequently no infections occurred. The composition was applied 3 times daily until full remission was achieved. Complete remission was present after 5 to 7 days.

15

EXAMPLE 5

In vivo with patients. Intact or ruptured blisters and sharp soreness of "cold sores" (herpes virus #1) on lips and adjacent oral regions of skin were terminated readily after topical daily applications of
20 10.0% pirfenidone hydrophilic ointment, and the lesions were gone in 5 to 10 days.

In vivo with patients. Various dermal facial warts (papilloma viruses) were eliminated by repeated daily applications of 10.0% pirfenidone hydrophilic
25 ointment, and the warts were gone in 3 to 6 weeks after initiating treatment with the ointment depending on the size of the wart.

EXAMPLE 6

30 As a barrier ointment or cream, pirfenidone hydrophilic ointment prevents the re-infection of previously treated microbial lesions, and has been repeatedly been observed in patients with various dermal cuts, traumatic injuries, and also in bed-ridden
35 patients with "bed sores".

-21-

EXAMPLE 7

An example of a modified USP hydrophilic ointment (10.0% pirfenidone) is as follows:

	Pirfenidone (USAN) Powder	100 gms
5	Propylene Glycol 400 USP	143 ml (143 gms)
	Sterile Distilled Water	417 ml (417 gms)
	Stearyl Alcohol USP	170 gms
	White Petrolatum	<u>170 gms</u>
	TOTAL:	1000 gms

10

EXAMPLE 8

An example of a vanishing cream formula (5.0% pirfenidone) is as follows:


	Pirfenidone (USAN) Powder	50 gms
15	Stearic Acid USP	30 gms
	Emplilan SE 40*	30 gms
	Isopropyl Myristate	30 gms
	Mineral Oil	115 gms
	Stearyl Alcohol USP	5 gms
20	Propylene Glycol 400 USP	50 gms
	Sterile Distilled Water	<u>690 ml (690 gms)</u>
	TOTAL:	1000 gms

* Trademark

25 Methods of preparation of pirfenidone and related compounds are described in US Patent No. 3,839,346, issued October 1, 1974, to Gadekar, and titled N-SUBSTITUTED PYRIDONES AND GENERAL METHOD FOR PREPARING PYRIDONES.

30 In addition to pirfenidone, 2-(1H) pyridone compounds having the following general structural formula have been shown to, or are expected to, have the same antiseptic properties, when applied in the concentrations and vehicles as described above with
35 respect to pirfenidone:

-22-



5

where: R1 = alkyl group (CH₃, C₂H₅, etc.); A is phenyl, thienyl, etc., or other aryl group. The alternate is for R3 to be the site of substitution of the alkyl group with R1 remaining as a hydrogen; R2 and R4 are, in every

10

circumstance, hydrogens.
Examples of the additional 2-(1H) pyridones include:

15

5-Methyl-1-(3-nitrophenyl)-2-(1H) pyridone
5-Methyl-1-(4'-methoxyphenyl)-2-(1H) pyridone
5-Methyl-1-p-tolyl-2-(1H) pyridone
5-Methyl-1-(3'-trifluoromethylphenyl)-2-(1H)
pyridone

20

1-(4'-Chlorophenyl)-5-Methyl-2-(1H) pyridone
5-Methyl-1-(2'-naphthyl)-2-(1H) pyridone
5-Methyl-1-(1'-naphthyl)-2-(1H) pyridone
3-Methyl-1-phenyl-2-(1H) pyridone
3-Ethyl-1-phenyl-2-(1H) pyridone
6-Methyl-1-phenyl-2-(1H) pyridone

25

3,6-Dimethyl-1-phenyl-2-(1H) pyridone
5-Methyl-1-(2'-Thienyl)-2-(1H) pyridone
1-(2'-Furyl)-5-Methyl-2-(1H) pyridone
5-Methyl-1-(5'-quinolyl)-2-(1H) pyridone
5-Methyl-1-(4'-pyridyl)-2-(1H) pyridone

30

5-Methyl-1-(3'-pyridyl)-2-(1H) pyridone
5-Methyl-1-(2'-pyridyl)-2-(1H) pyridone
5-Methyl-1-(2'-quinolyl)-2-(1H) pyridone
5-Methyl-1-(4'-quinolyl)-2-(1H) pyridone
5-Methyl-1-(2'-thiazolyl)-2-(1H) pyridone
1-(2'-Imidazolyl)-5-Methyl-2-(1H) pyridone

35

5-Ethyl-1-phenyl-2-(1H) pyridone
1-Phenyl-2-(1H) pyridone
1-(4'-Nitrophenyl)-2-(1H) pyridone
1,3-Diphenyl-2-(1H) pyridone

-23-

1-Phenyl-3-(4'-chlorophenyl)-2-(1H) pyridone
1,3-Diphenyl-5-methyl-2-(1H) pyridone
3-(4'-Chlorophenyl)-5-Methyl-1-phenyl-2-(1H)
pyridone, and
5 5-Methyl-3-phenyl-1-(2'-thienyl)-2-(1H)
pyridone.

It will thus be seen that the objects set forth
above, among those elucidated in, or made apparent from,
the preceding description, are efficiently attained and,
10 since certain changes may be made in the above
compositions and methods without departing from the
scope of the invention, it is intended that all matter
contained in the above description.

It is also to be understood that the following
15 claims are intended to cover all of the generic and
specific features of the invention herein described and
all statements of the scope of the invention which, as a
matter of language, might be said to fall therebetween.

20

25

30

35

-24-

Claims


1. An antiseptic topical pharmaceutical substance, comprising: an effective amount of one or
5 more 2-(1H) pyridone compound(s) in a suitable carrier medium.

2. An antiseptic topical pharmaceutical substance, as defined in Claim 1, wherein: said one or
10 more 2-(1H) pyridone compounds(s) is (are) present in an ointment, cream, or foam.

3. An antiseptic topical pharmaceutical substance, as defined in Claim 2, wherein: said one or
15 more 2-(1H) pyridone compounds(s) is (are) present in an aqueous dispersion of one or more substances.

4. An antiseptic topical pharmaceutical substance, as defined in Claim 1, wherein: said one or
20 more 2-(1H) pyridone compounds are present in a concentration of from about two weight percent to about 10 weight percent.

5. An antiseptic topical pharmaceutical
25 substance, as defined in Claim 1, wherein: said one or more 2-(1H) pyridone compounds have the following general structural formula:



where: R₁ = alkyl group (CH₃, C₂H₅, etc.); A is phenyl, thienyl, etc., or other aryl group; alternatively, R₃ is the site of substitution of said alkyl group with R₁
35 remaining as a hydrogen; and R₂ and R₄ are, in every circumstance, hydrogens.

-25-

6. An antiseptic topical pharmaceutical substance, as defined in Claim 5, wherein: said one or more 2-(1H) pyridone compounds are selected from the group consisting of:

- 5 5-Methyl-1-phenyl-2-(1H) pyridone
 5-Methyl-1-(3-nitrophenyl-2)-(1H) pyridone
 5-Methyl-1-(4'-methoxyphenyl)-2-(1H) pyridone
 5-Methyl-1-p-tolyl-2-(1H) pyridone
 5-Methyl-1-(3'-trifluoromethylphenyl)-2-(1H)
10 pyridone
 1-(4'Chlorophenyl)-5-Methyl-2-(1H) pyridone
 5-Methyl-1-(2'-naphthyl)-2-(1H) pyridone
 5-Methyl-1-(1'naphthyl)-2-(1H) pyridone
 3-Methyl-1-phenyl-2-(1H) pyridone
15 3-Ethyl-1-phenyl-2-(1H) pyridone
 6-Methyl-1-phenyl-2-(1H) pyridone
 3,6-Dimethyl-1-phenyl-2-(1H) pyridone
 5-Methyl-1-(2'-Thienyl)-2-(1H) pyridone
 1-(2'-Furyl)-5-Methyl-2-(1H) pyridone
20 5-Methyl-1-(5'-quinolyl)-2-(1H) pyridone
 5-Methyl-1-(4'-pyridyl)-2-(1H) pyridone
 5-Methyl-1-(3'-pyridyl)-2-(1H) pyridone
 5-Methyl-1-(2'-pyridyl)-2-(1H) pyridone
 5-Methyl-1-(2'-quinolyl)-2-(1H) pyridone
25 5-Methyl-1-(4'-quinolyl)-2-(1H) pyridone
 5-Methyl-1-(2'-thiazolyl)-2-(1H) pyridone
 1-(2'-Imidazolyl)-5-Methyl-2-(1H) pyridone
 5-Ethyl-1-phenyl-2-(1H) pyridone
 1-Phenyl-2-(1H) pyridone
30 1-(4'-Nitrophenyl)-2-(1H) pyridone
 1,3-Diphenyl-2-(1H) pyridone
 1-Phenyl-3-(4'-chlorophenyl)-2-(1H) pyridone
 1,3-Diphenyl-5-methyl-2-(1H) pyridone
 3-(4'-Chlorophenyl)-5-Methyl-1-phenyl-2-(1H)
35 pyridone, and
 5-Methyl-3-phenyl-1-(2'-thienyl)-2-(1H)
 pyridone.

-26-

7. An antiseptic topical compound, as defined in Claim 1, wherein: said pharmaceutical substance has the following composition, in weight percent:

	Pirfenidone (USAN) Powder	5.0
5	Propylene Glycol 400 USP	23.5
	Sterile Distilled Water	30.5
	Stearyl Alcohol USP	20.5
	White Petrolatum USP	<u>20.5</u>
	TOTAL:	100.0

10

8. An antiseptic topical compound, as defined in Claim 1, wherein: said pharmaceutical substance has the following composition, in weight percent:

	Pirfenidone (USAN) Powder	10.0
15	Propylene Glycol 400 USP	14.3
	Sterile Distilled Water	41.7
	Stearyl Alcohol USP	17.0
	White Petrolatum USP	<u>17.0</u>
	TOTAL:	100.0

20

9. An antiseptic topical compound, as defined in Claim 1, wherein: said pharmaceutical substance has the following composition, in weight percent:

	Pirfenidone (USAN) Powder	50 gms
25	Stearic Acid USP	30 gms
	Emplilan SE 40*	30 gms
	Isopropyl Myristate	30 gms
	Mineral Oil	115 gms
	Stearyl Alcohol USP	5 gms
30	Propylene Glycol 400 USP	50 gms
	Sterile Distilled Water	<u>690 ml (690 gms)</u>
	TOTAL:	1000 gms

35

-27-


10. A method of treating bacteria, fungi, and/or viruses on the surface of, or within, the layers of the dermis of skin, ears, fingernails, toenails, or hoofs of mammalian species, comprising: applying to said surface
5 or layers a pharmaceutical substance including an effective amount of one or more 2-(1H) pyridone compound(s).

11. A method, as defined in Claim 10, further
10 comprising: providing said one or more 2-(1H) pyridone compound(s) present in an ointment, cream, or foam.

12. A method, as defined in Claim 11, further
15 comprising: providing said one or more 2-(1H) pyridone compound(s) present in an aqueous dispersion of one or more substances.

13. A method, as defined in Claim 10, further
20 comprising: providing said one or more 2-(1H) pyridone compound(s) present in a concentration of from about two weight percent to about 10 weight percent.

14. A method, as defined in Claim 10, wherein:
25 said one or more 2-(1H) pyridone compound(s) have the following general structural formula:



30 where: R1 = alkyl group (CH₃, C₂H₅, etc.); A is phenyl, thienyl, etc., or other aryl group; alternatively, R3 is the site of substitution of said alkyl group with R1 remaining as a hydrogen; and R2 and R4 are, in every
35 circumstance, hydrogens.

-28-

15. A method, as defined in Claim 14, further comprising: providing said one or more 2-(1H) pyridone compound(s) selected from the group consisting of:

- 5-Methyl-1-phenyl-2-(1H) pyridone
- 5 5-Methyl-1-(3-nitrophenyl-2)-(1H) pyridone
- 5-Methyl-1-(4'-methoxyphenyl)-2-(1H) pyridone
- 5-Methyl-1-p-tolyl-2-(1H) pyridone
- 5-Methyl-1-(3'-trifluoromethylphenyl)-2-(1H)
pyridone
- 10 1-(4'Chlorophenyl)-5-Methyl-2-(1H) pyridone
- 5-Methyl-1-(2'-naphthyl)-2-(1H) pyridone
- 5-Methyl-1-(1'naphthyl)-2-(1H) pyridone
- 3-Methyl-1-phenyl-2-(1H) pyridone
- 3-Ethyl-1-phenyl-2-(1H) pyridone
- 15 6-Methyl-1-phenyl-2-(1H) pyridone
- 3,6-Dimethyl-1-phenyl-2-(1H) pyridone
- 5-Methyl-1-(2'-Thienyl)-2-(1H) pyridone
- 1-(2'-Furyl)-5-Methyl-2-(1H) pyridone
- 5-Methyl-1-(5'-quinolyl)-2-(1H) pyridone
- 20 5-Methyl-1-(4'-pyridyl)-2-(1H) pyridone
- 5-Methyl-1-(3'-pyridyl)-2-(1H) pyridone
- 5-Methyl-1-(2'-pyridyl)-2-(1H) pyridone
- 5-Methyl-1-(2'-quinolyl)-2-(1H) pyridone
- 5-Methyl-1-(4'-quinolyl)-2-(1H) pyridone
- 25 5-Methyl-1-(2'-thiazolyl)-2-(1H) pyridone
- 1-(2'-Imidazolyl)-5-Methyl-2-(1H) pyridone
- 5-Ethyl-1-phenyl-2-(1H) pyridone
- 1-Phenyl-2-(1H) pyridone
- 1-(4'-Nitrophenyl)-2-(1H) pyridone
- 30 1,3-Diphenyl-2-(1H) pyridone
- 1-Phenyl-3-(4'-chlorophenyl)-2-(1H) pyridone
- 1,3-Diphenyl-5-methyl-2-(1H) pyridone
- 3-(4'-Chlorophenyl)-5-Methyl-1-phenyl-2-(1H)
pyridone, and
- 35 5-Methyl-3-phenyl-1-(2'-thienyl)-2-(1H)
pyridone.

-29-

16. A method, as defined in Claim 10, further comprising: providing said pharmaceutical substance with the following composition, in weight percent:

	Pirfenidone (USAN) Powder	5.0
5	Propylene Glycol 400 USP	23.5
	Sterile Distilled Water	30.5
	Stearyl Alcohol USP	20.5
	White Petrolatum USP	<u>20.5</u>
	TOTAL:	100.0

10

17. A method, as defined in Claim 10, further comprising: providing said pharmaceutical substance with the following composition, in weight percent:

	Pirfenidone (USAN) Powder	10.0
15	Propylene Glycol 400 USP	14.3
	Sterile Distilled Water	41.7
	Stearyl Alcohol USP	17.0
	White Petrolatum USP	<u>17.0</u>
	TOTAL:	100.0

20

18. A method, as defined in Claim 10, further comprising: providing said pharmaceutical substance with the following composition, in weight percent:

	Pirfenidone (USAN) Powder	50 gms
25	Stearic Acid USP	30 gms
	Emplilan SE 40	30 gms
	Isopropyl Myristate	30 gms
	Mineral Oil	115 gms
	Stearyl Alcohol USP	5 gms
30	Propylene Glycol 400 USP	50 gms
	Sterile Distilled Water	<u>690 ml (690 gms)</u>
	TOTAL:	1000 gms

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/04412

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/445

US CL :514/315, 327

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/315, 327

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS-ONLINE, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3,974,281 A (GADEKAR) 10 August 1976, see the entire document.	1-18
X	US 5,179,098 A (CLOUGH et al.) 12 January 1993, see the entire document.	1-18
X	US 5,314,892 A (CLOUGH et al.) 24 May 1994, see the entire document.	1-18

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 MAY 1999

Date of mailing of the international search report

14 MAY 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KEVIN E. WEDDINGTON

Telephone No. (703) 308-1235

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

CJB